Search results
OP-1 Implant is an osteoinductive and osteoconductive bone graft material. It is supplied in a glass vial containing one gram of the device in the form of a sterile dry powder comprised of...
21 maj 2001 · Executive Summary. Orthopedic recombinant human protein European launch is slated for the third quarter following CE mark approval May 17. The device is indicated for treatment of non-union fractures of the tibia of at least nine months duration in skeletally mature patients in cases where previous autograft has failed or use of autograft is ...
OP-1 Putty consists of the recombinant human Osteogenic Protein (rhOP-1), Type I Bovine Bone Collagen Matrix (collagen matrix) and the Putty Additive carboxymethyl cellulose sodium (CMC).
1 lut 2011 · Stryker Corporation (NYSE: SYK) announced today the closing of the previously announced sale of its OP-1 product family, which includes OP-1 Implant, OP-1 Putty, Opgenra and Osigraft, for use in orthopaedic bone applications.
22 paź 2001 · Stryker plans to begin making its OP-1 (Osteogenic Protein 1) bone morphogenetic protein implant available in the U.S. by year-end under a humanitarian device exemption received from FDA Oct. 17, becoming the first company to have a BMP product reach the U.S. market.
1 maj 2008 · The purpose of this study was to evaluate the long-term safety and efficacy of OP-1 Putty as an alternative to autogenous bone for uninstrumented posterolateral fusion in this same patient population; these objectives were accomplished by comparing the radiographic and clinical outcomes as well as the respective complication rates of the OP-1 ...
17 maj 2001 · Stryker Corporation (NYSE: SYK) reported today that the European Commission has granted marketing authorization for Osteogenic Protein 1 (OP-1) in the 15 member countries of the European Union. Osteogenic Protein 1 is Stryker's patented recombinant human protein which induces bone formation.
